Table 3. Number of Events and Crude and Weighted Event Rates at 1-Year Follow-up According to Treatment for Main End Points and Selected Study Cohorts^a.

End Point/Cohort	Apixaban			Dabigatran			Rivaroxaban			Warfarin
	Events	Rate		Events	Rate		Events	Rate		Events	Rate
		Crude	Weighted		Crude	Weighted		Crude	Weighted		Crude	Weighted
Ischemic Stroke/SE
Main analysis cohort	10	0.86	0.83	22	0.70	0.65	14	1.09	1.20	57	0.79	0.81
Cohort hospitalized with AF	9	1.01	1.07	17	0.69	0.66	11	1.25	1.29	41	0.94	0.96
Low mortality cohort	9	1.00	1.00	19	0.75	0.79	10	0.97	0.92	38	0.68	0.70
All-Cause Death
Main analysis cohort	19	1.62	1.52	51	1.62	1.84	26	2.01	1.67	249	3.45	3.11
Cohort hospitalized with AF	14	1.56	1.40	36	1.46	1.60	15	1.69	1.50	107	2.44	2.33
Low mortality cohort	11	1.21	0.96	26	1.02	1.14	6	0.58	0.50	69	1.24	1.24
Any Bleeding
Main analysis cohort	8	0.68	0.57	23	0.74	0.73	17	1.33	1.38	109	1.52	1.53
Cohort hospitalized with AF	8	0.90	0.79	18	0.74	0.72	12	1.36	1.24	69	1.58	1.59
Low mortality cohort	5	0.55	0.44	15	0.59	0.58	11	1.06	1.02	70	1.26	1.32

Abbreviations: AF, atrial fibrillation; IPTW, inverse probability of treatment weighed; SE, systemic embolism.

^aCrude rates are events divided by person time per 100 years; weighted rates are based on IPTW population and express population mean treatment rates per 100 years.